In 2015, a multicentre Indian research team published “Genome-wide analysis correlates Ayurveda Prakriti” in Scientific Reports. The study did not perform whole-genome sequencing on 96 people. Investigators screened 3,416 healthy men aged 20–30 years and selected 262 participants with strongly expressed Vata-, Pitta-, or Kapha-dominant phenotypes. Classification by senior Ayurvedic physicians had to agree with an assessment produced by AyuSoft, a program based on features described in Ayurvedic literature.

The researchers used an Affymetrix genome-wide SNP array rather than whole-genome sequencing. They reported 52 SNPs that differed among the selected Prakriti groups at their stated statistical threshold after permutation testing. Of the 262 participants, 245 passed initial genotyping quality control, and smaller subsets were used after additional ancestry and outlier analyses. The investigators also examined PGM1, a gene involved in carbohydrate metabolism, as a possible correlate of features attributed to Pitta. They concluded that their preliminary findings supplied material for further study—not that a person’s complete Prakriti could be read directly from DNA.

This distinction matters. Prakriti is an Ayurvedic constitutional assessment based on a pattern of anatomical, physiological, psychological, and behavioural features. Genes may contribute to some of these features, but Prakriti is not equivalent to a single genotype, laboratory test, pulse finding, or consumer DNA report. “Ayurgenomics” is the research programme that investigates possible relationships between Ayurvedic phenotypes and modern genomic, epigenomic, transcriptomic, metabolic, and microbiome measurements. Its clinical applications remain investigational.

What Ayurgenomics Has Actually Found

Published studies have reported several associations, but they differ greatly in design, sample size, technology, and strength of evidence. Most examined selected groups of healthy people with strongly expressed constitutional features. They did not establish universal genetic profiles for every Vata, Pitta, or Kapha individual, and they did not validate genotype-based prescriptions for Ayurvedic medicines.

Research area Verified finding What it does not establish
HLA variation A small 2005 study reported differences in the distribution of certain HLA-DRB1 alleles among selected Prakriti groups. It does not provide an HLA test that can diagnose Prakriti or prescribe immune-modulating herbs.
Gene expression A 2008 exploratory study found differences in peripheral-blood gene expression and some biochemical and haematological measurements among extreme Vata, Pitta, and Kapha phenotypes. It does not prove that these expression patterns cause constitution-specific diseases.
Hypoxia physiology A 2010 study connected variation in the oxygen-sensing gene EGLN1, selected Prakriti phenotypes, and physiological responses relevant to high altitude. EGLN1 is not a general “Vata anxiety gene,” nor a validated marker for neurological prescribing.
CYP2C19 A study of 132 healthy participants reported an association between Prakriti groups and selected CYP2C19 genotypes, with extensive-metabolizer genotypes more frequent in its Pitta group and poor-metabolizer genotypes more frequent in its Kapha group. The result cannot be extended automatically to every CYP enzyme, botanical constituent, medicine, or person.
DNA methylation A 2015 study of 147 healthy men reported Prakriti-associated methylation signatures and validated selected regions involving LHX1, SOX11, and CDH22. Methylation differences do not by themselves prove causation or supply a treatment algorithm.
Genome-wide SNP analysis The 2015 Scientific Reports study reported 52 associated SNPs in a highly selected cohort and explored a PGM1 association with Pitta-related metabolic features. It did not create a clinically validated DNA test for Prakriti, disease risk, or herbal dosing.

These findings are scientifically interesting because they suggest that carefully defined Ayurvedic phenotypes may sometimes correspond to measurable biological variation. However, association is not identity or destiny. Results obtained in extreme, preselected groups may not generalize to people with mixed Vata-Pitta, Pitta-Kapha, Vata-Kapha, or relatively balanced constitutions. Replication in larger, diverse, independently assessed populations is still necessary.

Herb Metabolism and the CYP450 Question

Cytochrome P450 enzymes participate in the metabolism of many medicines and other substances, and inherited variants in certain CYP genes can affect the handling of specific pharmaceutical drugs. The verified Prakriti study in this area examined selected CYP2C19 variants. It did not show that all Pitta individuals rapidly metabolize herbs or that all Kapha individuals require lower doses.

It is therefore incorrect to claim that CYP3A4 or CYP3A5 variants have been shown to make Pitta individuals require 30–50% more Ashwagandha or Turmeric. Likewise, the cited research does not demonstrate that CYP2C19 determines the safe dose of Pippali, or that CYP1A2 can be used to select doses of Tulsi, Neem, or Brahmi. A botanical preparation contains numerous constituents, and its absorption, transformation, transport, and elimination may involve several enzymes and non-CYP pathways. The plant part, extract method, formulation, food intake, other medicines, liver and kidney function, age, and product quality can all influence exposure.

Even when a pharmacogenetic result is clinically meaningful for a named prescription drug, it cannot be transferred automatically to an Ayurvedic herb that happens to interact with the same enzyme in a laboratory experiment. A clinically useful dosing rule requires validated information connecting a particular variant, a standardized preparation, measured exposure, safety, and patient outcomes. Such genotype-to-dose guidelines have not been established for Ashwagandha, Brahmi, Triphala, Turmeric, or Pippali.

Disease Vulnerability Is Not Yet Predictable from Prakriti Genomics

Ayurveda considers constitution when evaluating susceptibility, strength, prognosis, and treatment, but modern statements such as “Vata equals neurological disease,” “Pitta equals inflammatory disease,” or “Kapha equals diabetes” are oversimplifications when presented as fixed predictions. Classical assessment also considers the current disorder, affected tissues, digestive capacity, suitability, age, environment, season, strength, and numerous other factors.

No verifiable 2019 PLoS One study was found showing that Kapha-dominant people had higher polygenic risk scores for type 2 diabetes or metabolic syndrome while Vata-dominant people had higher scores for osteoporosis and anxiety. That claim should not be used to market Prakriti assessment as a genomic disease-screening test. Existing studies have identified exploratory associations with selected physiological measurements or disease cohorts, but they have not produced validated Prakriti-specific polygenic scores suitable for diagnosis, prevention, or treatment decisions.

Prakriti assessment may still contribute to a practitioner’s broader understanding of a patient, especially within traditional Ayurvedic clinical reasoning. It must not replace established screening for diabetes, cardiovascular disease, osteoporosis, cancer, psychiatric illness, or other conditions. Family history, symptoms, physical examination, validated risk calculators, and appropriate laboratory or imaging investigations remain essential.

The Microbiome Dimension

Prakriti-associated microbiome research is also preliminary. A 2018 study examined 16S rRNA profiles from 50 men and 63 women in a comparatively homogeneous rural population. Firmicutes and Bacteroidetes were the major phyla across all three groups. Overall alpha-diversity patterns were comparable, and beta-diversity analysis did not separate participants into clear Prakriti clusters. The investigators did identify certain less-abundant taxa that were enriched in particular groups, with notable differences between male and female results.

Smaller studies published in 2019 and 2021 likewise reported differences in the relative abundance of selected gut, oral, or skin organisms among Prakriti groups. These investigations are useful for generating hypotheses, but they do not prove that Kapha constitution inherently has low microbial diversity, a high Firmicutes-to-Bacteroidetes ratio, or a microbiome equivalent to metabolic syndrome.

There is consequently no validated rule for choosing probiotics, fermented foods, Triphala, or other interventions from Prakriti microbiome data. Microbiome composition is affected by diet, location, medications, sanitation, age, recent illness, sequencing methods, and many other variables. Commercial stool reports also vary in analytical quality and often lack proven clinical utility for prescribing treatment in otherwise healthy people.

Rasayana Selection: Classical Individualization, Not Genomic Matching

Classical Ayurveda already provides a detailed framework for individualization, but it is broader than genetic testing. Charaka Samhita, Vimana Sthana 8, describes a tenfold examination that considers the patient’s habitat and body, Prakriti and Vikriti, tissue excellence, compactness and build, measurements, suitability or habituation, mental strength, capacity for food and digestion, exercise capacity, and age. The text also warns that the strength and potency of treatment must be chosen after considering the patient and disease; otherwise medicine may cause harm.

This framework does not support selecting Ashwagandha from an FKBP5 result, Brahmi from the BDNF Val66Met variant, Triphala from a presumed Kapha microbiome signature, or Curcumin from inflammatory SNPs. Research on these plants and molecular pathways may offer hypotheses, but no clinical trials have validated those specific gene-herb matching rules. Fixed extract doses such as 600 or 900 mg of Ashwagandha, 300–450 mg of Brahmi, or 5 g of Triphala cannot be prescribed responsibly from genotype or Prakriti alone.

The Ayurvedic Pharmacopoeia of India serves a different purpose. Its monographs establish official standards concerned with the identity, purity, and strength of Ayurvedic drugs and ingredients. Pharmacopoeial quality is important, but the Pharmacopoeia does not certify genotype-specific indications or doses. A correctly identified, uncontaminated herb can still be unsuitable for a particular person, interact with medicines, or be used in an inappropriate preparation or amount.

What Responsible Precision Ayurveda Can Mean Today

A defensible form of precision Ayurveda begins with careful clinical assessment rather than a commercial gene report. It may integrate a qualified Ayurvedic evaluation with conventional diagnosis, medication review, laboratory findings, dietary history, allergies, organ function, pregnancy status, and monitoring of benefits and adverse effects. Genomics may be added when a healthcare professional identifies a medically established reason, such as a pharmacogenetic test linked to a particular prescription drug.

Ayurgenomics can also contribute at the research level by improving phenotype definition. Instead of grouping all patients with a biomedical diagnosis together, researchers may examine whether rigorously assessed constitutional patterns identify subgroups with different biomarkers or responses. For that approach to become clinically useful, assessment methods must be reproducible, studies must be prospectively registered and adequately powered, and results must be independently replicated before treatment recommendations are made.

Future work may eventually identify reliable relationships among Prakriti, genomics, epigenetics, metabolomics, microbiome patterns, drug response, and clinical outcomes. At present, however, the evidence supports continued investigation rather than routine genomic selection of rasayana herbs or constitution-based alteration of doses.

Using Consumer Genetic Data Safely

Direct-to-consumer DNA services commonly test a selected set of variants rather than providing a complete clinical analysis. A negative consumer result cannot rule out all medically important variants, and an apparently actionable result may need confirmation in a clinical laboratory. The National Human Genome Research Institute also notes that some consumer tests promote traits or interventions without a confirmed gene-to-phenotype relationship or demonstrated clinical utility.

Uploading raw DNA data to a third-party interpretation platform does not turn it into a validated Ayurvedic prescribing tool. Reports may differ because platforms use different databases, assumptions, and variant classifications. Privacy and data-sharing policies should also be reviewed before uploading genomic files. Most importantly, a list of CYP, BDNF, COMT, MTHFR, APOE, or HLA variants should not be used independently to start, stop, increase, or reduce an herbal or pharmaceutical treatment.

Actionable tip: Keep a complete list of medicines, Ayurvedic formulations, extracts, teas, and supplements you use, including brand, plant part, dose, and frequency. Share the list with both your Ayurvedic physician and conventional healthcare provider. When a genetic result appears medically important, request interpretation by a clinician or genetic counsellor familiar with the relevant condition or drug. Do not adjust Ashwagandha, Brahmi, Triphala, Turmeric, Pippali, or any prescription medicine solely from an online genotype report.

Ayurgenomics and genomic-guided Ayurveda remain emerging research fields. The associations described here are not established diagnostic tests or clinical dosing protocols. Consult a qualified Ayurvedic physician and an appropriately trained healthcare provider before using medicinal herbs, combining them with prescription drugs, or acting on pharmacogenetic or direct-to-consumer DNA results.

References

  1. Nature (nature.com)
  2. Link (link.springer.com)
  3. Link (link.springer.com)
  4. Classification of human population based on HLA gene polymorphism and the concept of Prakriti in Ayurveda (2005), PubMed
  5. EGLN1 involvement in high-altitude adaptation revealed through genetic analysis of extreme constitution types defined in Ayurveda (2010), PubMed
  6. Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability (2011), PubMed Central
  7. Frontiersin (frontiersin.org)
  8. Understanding the association between the human gut, oral and skin microbiome and the Ayurvedic concept of prakriti (2019), PubMed
  9. Exploring the signature gut and oral microbiome in individuals of specific Ayurveda prakriti (2021), PubMed
  10. Charaka Samhita — Rogabhishagjitiya Vimana
  11. Ayurvedic Pharmacopoeia of India
  12. Ayurvedic Pharmacopoeia of India
  13. Ayurgenomics-based frameworks in precision and integrative medicine: Translational opportunities (2023), PubMed Central
  14. Genome (genome.gov)
Tags: Future Gene Variants Genomics personalized medicine Precision Ayurveda research SNP